Menu
Subscribe to our Newsletter
Karolinska Institutet is a renowned public institution at the cutting edge of medical research. Karolinska Institutet (KI) is one of the world’s leading medical universities, located in Stockholm, Sweden.
Founded in 1810, KI is renowned for its significant contributions to medical research and education. It is closely associated with the Nobel Assembly. KI is recognized for its cutting-edge research in various fields, including regenerative medicine, neuroscience, immunology, and cancer.
The Department of Laboratory Medicine – Biomolecular Medicine and Advanced Therapies is committed to studying efficient means of delivering promising therapeutics to the right organ with the right dose, offering groundbreaking solutions to make promising therapeutic approaches available to patients.
Currently, characterization of EVs and LNPs uses methods that are destructive and don’t allow for particle analysis in their native form. Determining therapeutic cargo loading and batch consistency is complex. Size, polydispersity, and concentration measurements are obtained using dynamic light scattering and nanoparticle tracking analysis.
However, the variability in EV and LNP formulations makes capturing accurate data challenging. These methods
require preprocessing, limiting direct and online measurements. Thus, there’s a strong need for precise, non-destructive characterization techniques to advance biological therapeutics.
We were looking for innovative solutions using advanced technologies to overcome the current solution’s limitations.
Compulsory requirements:
iLoF is a digital health company pioneering a breakthrough AI-powered photonics platform to accelerate the future of drug development and personalized medicine. Our team of dedicated physicists, biologists, and data scientists is partnering with world-class leading institutes and companies to unlock the full potential of this innovative approach.
iLoF, founded in 2019, has already been featured as one of the most disruptive companies in Europe, and is backed by several top-tier investors, having received multiple awards and grants, underscoring the groundbreaking potential of it’s innovative platform.
iLoF’s cutting-edge solution provides a multi-parameter analytical platform for the characterization of biophysical and chemical properties of complex nanoformulations, like extracellular vesicles (EVs) and lipid nanoparticles (LNP). By leveraging multi-dimensional optical data, our platform delivers next-generation profiling of nanoparticles in liquid specimens, with key benefits including:
iLoF maximizes user experience by simplifying sample processing and providing automatic sample handling, remote monitoring, and expedited data analysis. By equipping drug developers with actionable insights, this innovative tool is designed to enable real-time, atline nanoparticle analytics with unparalleled accuracy and efficiency, streamlining the development and production of advanced nanotherapeutics.
The proposed solution aligns with the Challenger’s needs for developing advanced therapeutics, namely:
This project has received funding from the European Union’s Horizon Europe research and innovation programme under the Grant Agreement 101071212.
Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Innovation Council and SMEs Executive Agency (EISMEA). Neither the European Union nor the granting authority can be held responsible for them.
